Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,672 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific keynote: molecular therapeutics in ovarian cancer.
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Among authors: hasegawa y. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.
Lysophosphatidic acid is a bioactive mediator in ovarian cancer.
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Fang X, et al. Among authors: hasegawa y. Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. doi: 10.1016/s1388-1981(02)00179-8. Biochim Biophys Acta. 2002. PMID: 12069836 Review.
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Mills GB, et al. Among authors: hasegawa y. Cancer Treat Res. 2002;107:259-83. doi: 10.1007/978-1-4757-3587-1_12. Cancer Treat Res. 2002. PMID: 11775454 Review.
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. Tanyi JL, et al. Among authors: hasegawa y. Cancer Res. 2003 Mar 1;63(5):1073-82. Cancer Res. 2003. PMID: 12615725
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Tanyi JL, et al. Among authors: hasegawa y. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45. Clin Cancer Res. 2003. PMID: 14506139
Lysophosphatidic acid production and action: validated targets in cancer?
Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Umezu-Goto M, et al. Among authors: hasegawa y. J Cell Biochem. 2004 Aug 15;92(6):1115-40. doi: 10.1002/jcb.20113. J Cell Biochem. 2004. PMID: 15258897 Review.
4,672 results